Vanda Pharmaceuticals (NASDAQ:VNDA) CFO Kevin Patrick Moran Sells 42,442 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CFO Kevin Patrick Moran sold 42,442 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $350,995.34. Following the transaction, the chief financial officer directly owned 411,380 shares in the company, valued at approximately $3,402,112.60. This represents a 9.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock traded down $0.10 during trading on Thursday, hitting $8.10. The company’s stock had a trading volume of 195,341 shares, compared to its average volume of 2,844,654. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. The company has a market cap of $478.79 million, a PE ratio of -2.17 and a beta of 0.55. The business has a fifty day moving average of $7.56 and a 200-day moving average of $5.97. Vanda Pharmaceuticals Inc. has a 52 week low of $3.81 and a 52 week high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The business had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. As a group, research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA granted a formal evidentiary public hearing to review CDER’s proposed refusal to approve Vanda’s sNDA for HETLIOZ in jet‑lag disorder — a rare, high‑visibility procedural win that gives Vanda a public forum to challenge the refusal and could materially improve approval odds if the hearing goes well. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ
• Positive Sentiment: Truist initiated coverage with a “Buy” rating and an $18 price target (~119% upside vs. current levels) — a new bullish analyst voice that can attract buyers and volume. Truist starts Vanda at Buy $18 (Benzinga)
• Positive Sentiment: HC Wainwright reiterated a Buy and published 2027 quarterly EPS forecasts (and a $24 price target) — another sizable upside target that supports constructive sentiment among growth/biotech investors. HC Wainwright issues estimates, Buy $24 PT
• Neutral Sentiment: Analyst coverage is mixed: while several firms maintain Buy/Overweight calls and high targets, there are recent downgrades and a consensus “Moderate Buy” with an average target near $14.90 — constructive overall but not unanimous. MarketBeat analyst summary
• Negative Sentiment: Multiple senior insiders sold sizable blocks of shares on/around March 2 (CEO, CFO, CMO, and SVPs combined disclosed sales totaling roughly $2.6M+) — coordinated insider selling often creates short‑term supply and can be perceived negatively by the market. Vanda’s Top Brass Quietly Unload a Wave of Shares (TipRanks)
• Negative Sentiment: SEC filings formally disclose the individual insider trades (CEO filing and others), making the sales official and giving investors precise sizes/prices to evaluate motives (tax, diversification, or signal). SEC filing — CEO ownership disclosure

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Truist Financial initiated coverage on shares of Vanda Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $18.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Zacks Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.90.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $25,000. Bailard Inc. raised its stake in shares of Vanda Pharmaceuticals by 16.2% during the 2nd quarter. Bailard Inc. now owns 26,100 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 3,631 shares during the period. Panagora Asset Management Inc. raised its stake in shares of Vanda Pharmaceuticals by 3.4% during the 4th quarter. Panagora Asset Management Inc. now owns 118,987 shares of the biopharmaceutical company’s stock valued at $1,049,000 after purchasing an additional 3,928 shares during the period. Jane Street Group LLC lifted its holdings in Vanda Pharmaceuticals by 6.1% during the 2nd quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock worth $373,000 after purchasing an additional 4,533 shares in the last quarter. Finally, Savant Capital LLC boosted its stake in Vanda Pharmaceuticals by 30.3% in the 3rd quarter. Savant Capital LLC now owns 22,493 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 5,229 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.